AKBLF
Price
$28.20
Change
+$0.55 (+1.99%)
Updated
Jul 2 closing price
Capitalization
6.51B
URGN
Price
$13.58
Change
+$0.62 (+4.78%)
Updated
Jul 3 closing price
Capitalization
626.14M
45 days until earnings call
Interact to see
Advertisement

AKBLF vs URGN

Header iconAKBLF vs URGN Comparison
Open Charts AKBLF vs URGNBanner chart's image
Alk Abello AS
Price$28.20
Change+$0.55 (+1.99%)
Volume$65
Capitalization6.51B
UroGen Pharma
Price$13.58
Change+$0.62 (+4.78%)
Volume$737.41K
Capitalization626.14M
AKBLF vs URGN Comparison Chart in %
Loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBLF vs. URGN commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBLF is a Hold and URGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (AKBLF: $28.20 vs. URGN: $13.58)
Brand notoriety: AKBLF and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBLF: 934% vs. URGN: 20%
Market capitalization -- AKBLF: $6.51B vs. URGN: $626.14M
AKBLF [@Biotechnology] is valued at $6.51B. URGN’s [@Biotechnology] market capitalization is $626.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBLF’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • AKBLF’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBLF is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBLF’s TA Score shows that 3 TA indicator(s) are bullish while URGN’s TA Score has 6 bullish TA indicator(s).

  • AKBLF’s TA Score: 3 bullish, 2 bearish.
  • URGN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, URGN is a better buy in the short-term than AKBLF.

Price Growth

AKBLF (@Biotechnology) experienced а +1.99% price change this week, while URGN (@Biotechnology) price change was +3.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

URGN is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBLF($6.51B) has a higher market cap than URGN($626M). URGN (27.512) and AKBLF (26.174) have similar YTD gains . AKBLF has higher annual earnings (EBITDA): 1.55B vs. URGN (-119.79M). AKBLF has more cash in the bank: 517M vs. URGN (196M). URGN has less debt than AKBLF: URGN (125M) vs AKBLF (800M). AKBLF has higher revenues than URGN: AKBLF (5.71B) vs URGN (91.9M).
AKBLFURGNAKBLF / URGN
Capitalization6.51B626M1,040%
EBITDA1.55B-119.79M-1,296%
Gain YTD26.17427.51295%
P/E Ratio42.64N/A-
Revenue5.71B91.9M6,211%
Total Cash517M196M264%
Total Debt800M125M640%
FUNDAMENTALS RATINGS
AKBLF vs URGN: Fundamental Ratings
AKBLF
URGN
OUTLOOK RATING
1..100
5091
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
44100
SMR RATING
1..100
49100
PRICE GROWTH RATING
1..100
4235
P/E GROWTH RATING
1..100
84100
SEASONALITY SCORE
1..100
4575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

URGN's Valuation (73) in the Biotechnology industry is in the same range as AKBLF (82) in the null industry. This means that URGN’s stock grew similarly to AKBLF’s over the last 12 months.

AKBLF's Profit vs Risk Rating (44) in the null industry is somewhat better than the same rating for URGN (100) in the Biotechnology industry. This means that AKBLF’s stock grew somewhat faster than URGN’s over the last 12 months.

AKBLF's SMR Rating (49) in the null industry is somewhat better than the same rating for URGN (100) in the Biotechnology industry. This means that AKBLF’s stock grew somewhat faster than URGN’s over the last 12 months.

URGN's Price Growth Rating (35) in the Biotechnology industry is in the same range as AKBLF (42) in the null industry. This means that URGN’s stock grew similarly to AKBLF’s over the last 12 months.

AKBLF's P/E Growth Rating (84) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that AKBLF’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBLFURGN
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
24%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
20%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
33%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
34%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
N/A
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
37%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RCGTX15.000.21
+1.42%
Virtus Zevenbergen Technology C
UBPSX15.890.18
+1.15%
ProFunds UltraLatin America Svc
NCGFX67.480.56
+0.84%
New Covenant Growth
RYSYX78.970.65
+0.83%
Rydex S&P 500 C
ITHSX54.970.42
+0.77%
Hartford Capital Appreciation R4

AKBLF and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBLF has been loosely correlated with CRDF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBLF jumps, then CRDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBLF
1D Price
Change %
AKBLF100%
N/A
CRDF - AKBLF
37%
Loosely correlated
+1.95%
MSCLF - AKBLF
28%
Poorly correlated
N/A
NGNE - AKBLF
25%
Poorly correlated
+4.69%
ADIL - AKBLF
25%
Poorly correlated
-0.97%
URGN - AKBLF
23%
Poorly correlated
+4.78%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with AIM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then AIM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
+4.78%
AIM - URGN
39%
Loosely correlated
-3.47%
ETNB - URGN
38%
Loosely correlated
+0.59%
ATXS - URGN
36%
Loosely correlated
+1.40%
SCPH - URGN
36%
Loosely correlated
-1.73%
PHAT - URGN
35%
Loosely correlated
+0.11%
More